Free Trial
NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.12
$4.83
50-Day Range
N/A
52-Week Range
N/A
Volume
81,361 shs
Average Volume
68,651 shs
Market Capitalization
$47.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Elicio Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
113.7% Upside
$10.00 Price Target
Short Interest
Healthy
0.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.67) to ($3.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.74 out of 5 stars

Medical Sector

638th out of 897 stocks

Pharmaceutical Preparations Industry

302nd out of 426 stocks

ELTX stock logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

ELTX Stock News Headlines

J.P. Morgan’s DIRE Warning
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
J.P. Morgan’s DIRE Warning
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
See More Headlines
Receive ELTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
7/23/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+113.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-35,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.30 million
Book Value
$1.35 per share

Miscellaneous

Free Float
8,216,000
Market Cap
$47.88 million
Optionable
Not Optionable
Beta
0.54
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

ELTX Stock Analysis - Frequently Asked Questions

How were Elicio Therapeutics' earnings last quarter?

Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by $0.06.

When did Elicio Therapeutics IPO?

Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

This page (NASDAQ:ELTX) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners